SORAFENIB TOSYLATE generics — when can they launch?
SORAFENIB TOSYLATE (SORAFENIB TOSYLATE) · · 2 active US patents · 0 expired
Where SORAFENIB TOSYLATE sits in the generic timeline
Imminent generic cliff: earliest active US patent for SORAFENIB TOSYLATE expires in 2027 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 2 patents
FDA U-codes carved out by SORAFENIB TOSYLATE patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-1624 | (no description) |
U-2107 | (no description) |
Sample patent estate
Showing 2 of 2 active US patents. View full estate on the SORAFENIB TOSYLATE drug page →
-
This patent protects a thermodynamically stable form of the tosylate salt of a specific chemical compound, used in medicaments.USPTO title: Thermodynamically stable form of a tosylate salt
-
This patent protects a pharmaceutical composition for treating cancer, either alone or in combination with other cancer therapies.USPTO title: Pharmaceutical composition for the treatment of cancer
Sources
- FDA Orange Book — patents listed against SORAFENIB TOSYLATE (NDA filed 2005)
- SORAFENIB TOSYLATE drug profile — full patent estate, indications, clinical trials, pricing
- Patent cliff 2027 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on SORAFENIB TOSYLATE — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →